Clinical trials: Clinically Significant Portal Hypertension
Hepatic Carcinoma
Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
Clinically significant portal hypertension limits the therapeutic options for hepatocellular carcinoma (HCC), which is closely associated with patient prognosis.
- Trial name
- NCT06245798
- Testing
- transarterial chemoembolisation
- Where
- 2 sites in China
- Volunteers
- 3,000 people
- Sponsor
- Tang-Du Hospital
Portal Hypertension
Direct Portal Pressure Measurement Via Endoscopic Ultrasound in Advanced Chronic Liver Disease (EVADIPP)
A minimally invasive procedure to directly assess portal pressure gradient under endoscopic ultrasound guidance (EUS-PPG) has become available and initial data have proved the technique to be safe.
- Trial name
- EVADIPP (NCT06266260)
- Testing
- EUS PPG measurement
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Chronic Hepatitis C, Cirrhosis
Transient Elastography to Assess Liver Fibrosis and Portal Hypertension in HCV Cirrhotic Patients Treated With New Antiviral Drugs (SPLEEN-C)
The purpose of this study is to evaluate the effects of sustained virological response in liver and spleen stiffness in patients with HCV compensated advanced chronic liver disease treated with new all oral antiviral drugs in…
- Conditions
- Chronic Hepatitis C, Cirrhosis, Portal Hypertension
- Trial name
- SPLEEN-C (NCT02439567)
- Testing
- Fibroscan: Liver and Spleen elastography
- Where
- Spain
- Volunteers
- 41 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Portal Hypertension
Acute Hemodynamic Response to Carvedilol in Children With Clinically Significant Portal Hypertension.
Clinically significant portal hypertension (CSPH) is defined as Hepatic Venous Pressure gradient (HVPG) >10 mmHg. Patients with CSPH are at risk of developing esophageal varices and clinical decompensation (variceal bleeding…
- Trial name
- NCT05767229
- Testing
- Carvedilol
- Where
- India
- Volunteers
- 40 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Compensated Liver Disease, Esophageal Varices
Baveno VIII Criteria for Portal Hypertension in Egyptian Patients
This prospective observational study aims to validate Baveno VIII criteria for detection of clinically significant portal hypertension and to evaluate additional predictors of esophageal varices in Egyptian patients with…
- Conditions
- Compensated Liver Disease, Esophageal Varices, Portal Hypertension, Chronic Liver Disease
- Trial name
- NCT07842666
- Volunteers
- 125 people
- Sponsor
- Assiut University
Clinically Significant Portal Hypertension
The Effect of Sorafenib on Portal Pressure
Sorafenib is approved by the US FDA for the treatment of unresectable (can not operate) liver cancer and for renal cell carcinoma.
- Trial name
- NCT01714609
- Testing
- Sorafenib
- Where
- 6 sites in United States
- Volunteers
- 10 people
- Sponsor
- Yale University
Asymptomatic Cirrhosis, Clinically Significant Portal Hypertension
Effect of Long-term Carvedilol to Prevent Decompensation or Death in Patients With Asymptomatic Child-Pugh A5 to B8 Cirrhosis and Clinically Significant Portal Hypertension: a Multicenter Double-blind Randomized Control Trial
Decompensation of cirrhosis is a turning point in cirrhosis course, as associated with a marked decrease in life expectancy. Thus, prevention of decompensation is crucial.
- Trial name
- CARVECIR (NCT06263816)
- Testing
- Experimental group: Patients will be treated with carvedilol.
- Where
- 24 sites in France
- Volunteers
- 290 people
- Sponsor
- University Hospital, Tours
Hypertension, Portal
A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver)
This study is open to adults with liver cirrhosis and high blood pressure in the portal vein (main vessel going to the liver). The purpose of this study is to find out whether a medicine called Avenciguat helps people with this…
- Trial name
- NCT05161481
- Testing
- Avenciguat (BI 685509)
- Where
- 45 sites in United States, Argentina and 20 more
- Volunteers
- 80 people
- Sponsor
- Boehringer Ingelheim
Portal Hypertension, Clinically Significant Portal Hypertension
Assessment of Portal Hypertension With Multiparametric MRI
The purpose of this study is to determine whether new multiparametric magnetic resonance imaging (MRI) methods (including diffusion-weighted MRI, dynamic contrast-enhanced MRI, MR elastography and phase-contrast imaging) can be…
- Trial name
- NCT03436550
- Testing
- mpMRI, ARFI US
- Where
- United States
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Icahn School of Medicine at Mount Sinai
Hypertension, Portal
Radiomics Signature of Hepatic Venous Pressure Gradient (rHVPG) With CT Angiography (CHESS1701)
This is a prospective, multi-center diagnostic trial conducted at 5 high-volume liver centers in China designed to determine the diagnostic performance of radiomics-based hepatic venous pressure gradient (rHVPG) (investigational…
- Trial name
- rHVPG (NCT03138915)
- Testing
- HVPG measurement, CTA
- Where
- 6 sites in China
- Volunteers
- 385 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Liver Cirrhosis, Portal Hypertension.
Hemodynamic Effect of Simvastatin With Beta Blockers in Clinical Portal Hypertension
In the genesis and maintenance of PH associated with liver cirrhosis are two mechanisms that act synergistically. The first is an increase in hepatic vascular resistance, due in part to the disruption of liver structure inherent…
- Trial name
- SIMBETA (NCT01282385)
- Testing
- Simvastatin
- Where
- Spain
- Volunteers
- 60 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Non-Cirrhotic Portal Hypertension, Common Variable Immunodeficiency
Prediction of Portal Hypertension in Patients With CVID (CVID-pHT)
Patients with CVID will be offered to participate in this observational trial during the routine annual visit in the outpatient clinic at the Center of chronic Immunodeficiency (CCI) of the University Medical Center Freiburg…
- Trial name
- CVID-pHT (NCT06145100)
- Testing
- Ultrasound including color doppler ultrasound
- Where
- Germany
- Volunteers
- 250 people
- Sponsor
- University Hospital Freiburg
Clinically Significant Portal Hypertension
The Impact of Carvedilol Posology on Clinically Significant Portal Hypertension
Carvedilol has emerged as the preferred non-selective β-blocker (NSBB) for treating portal hypertension. However, there is still a debate in dosing regimen, specially regarding dose interval, with a potential lower bioavalability…
- Trial name
- NCT06015373
- Testing
- supress the night dose of carvedilol
- Where
- Portugal
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Centro Hospitalar De São João, E.P.E.
Hypertension, Portal
MR-based Models for Clinically Significant Portal Hypertension in Cirrhosis (CHESS1802)
Clinically significant portal hypertension (CSPH) is associated with an incremental risk of esophageal varices and overt clinical decompensations in cirrhosis.
- Trial name
- NCT03766880
- Testing
- Transjugular HVPG measurement, MR imaging
- Where
- 11 sites in China, Turkey (Türkiye)
- Volunteers
- 175 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hypertension, Portal, Liver Cirrhosis
A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly
This study is open to adults with advanced liver cirrhosis caused by hepatitis B, hepatitis C, alcohol-related liver disease, non-alcoholic steatohepatitis or other causes.
- Trial name
- NCT06082843
- Testing
- Avenciguat
- Where
- 15 sites in United States, Austria and 8 more
- Volunteers
- 22 people
- Sponsor
- Boehringer Ingelheim
Bariatric Surgery Candidate, Obesity, Morbid
Portal Hypetension and Bariatric Surgery (BARIAPORTAL)
The worldwide obesity epidemic has led to an increase in the proportion of patients with chronic liver disease due to non-alcoholic fatty liver disease (NAFLD) and in the prevalence of obesity in patients with cirrhosis of all…
- Conditions
- Bariatric Surgery Candidate, Obesity, Morbid, Portal Hypertension
- Trial name
- BARIAPORTAL (NCT05653115)
- Testing
- Bariatric surgery
- Where
- France
- Volunteers
- 63 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Hypertension, Portal
Virtual Hepatic Venous Pressure Gradient (vHVPG) With CT Angiography (CHESS1601)
This is a prospective, multi-center trial conducted at 1 Guangzhou and 2 Beijing centers designed to determine the diagnostic performance of virtual hepatic venous pressure gradient (vHVPG) (investigational technology) by…
- Trial name
- vHVPG (NCT02842697)
- Testing
- HVPG measurement, CTA, Doppler ultrasound
- Where
- 3 sites in China
- Volunteers
- 102 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Hepatocellular Carcinoma With CSPH
Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma
The aim of this study is to compare the operative complication and short-/long-term therapeutic effects of percutaneous local ablative therapy (PLAT) versus surgical resection(SR) on small hepatocellular carcinoma(HCC) patients…
- Trial name
- NCT01860222
- Testing
- SR, PLAT
- Where
- 2 sites in China
- Volunteers
- 160 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Liver Cirrhosis, Portal Hypertension
Value of Von Willebrand Factor in Portal Hypertension
In patients with liver cirrhosis elevated levels of von Willebrand factor antigen (vWF-Ag) are found frequently but the clinical significance is unclear.
- Trial name
- NCT01358123
- Where
- Austria
- Volunteers
- 300 people
- Sponsor
- Medical University of Vienna
Liver Transplant With Clinically Significant Portal Hypertension
Evaluation of Efficacy and Safety of Somatostatin Used as Inflow Modulator in Liver Transplantation.
This study is a 5 day, single-center, randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of Somatostatin used as inflow modulator in liver transplantation.
- Trial name
- NCT01290172
- Testing
- Administration of Somatostatin
- Where
- Belgium
- Volunteers
- 33 people
- Sponsor
- University Hospital, Ghent